Korea S.E.
03:30:00 27/05/2024 am IST
5-day change
1st Jan Change
1,515
KRW
-2.70%
-6.48%
-31.29%
18/04
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
CI
27/03
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
September 18, 2023 at 09:30 am IST
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
18/04
CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
27/03
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
18/03
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
21/02
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
21/02
CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on August 21, 2023, has expired with 2,340,000 shares, representing 3.52% for KRW 4,980.33 million.
20/02
CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
25/01
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
21/11
CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
12/23/12
CI
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
18/23/18
CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
21/23/21
CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
21/23/21
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
22/22/22
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
19/22/19
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
19/22/19
CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 1,519,180 shares, representing 2.23% for KRW 4,999.11 million.
19/22/19
CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
17/22/17
CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
16/22/16
CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
16/22/16
CI
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 5.0000013 billion in funding from Osung Advanced Materials Co., Ltd.
28/22/28
CI
The E&M Co., Ltd. announced that it has received KRW 5 billion in funding from Hwail Pharmaceutical Co.,Ltd.
22/22/22
CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 5.0000013 billion in funding from Osung Advanced Materials Co., Ltd.
04/22/04
CI
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) added to S&P Global BMI Index
20/21/20
CI
The E&M Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Hwail Pharmaceutical Co.,Ltd.
20/21/20
CI
CTCBIO Inc. announced that it has received KRW 9.999985977 billion in funding from Bridge Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
01/21/01
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-31.29% 83.92M +38.51% 727B +31.74% 594B -6.23% 354B +18.78% 328B +1.35% 277B +16.00% 243B +8.44% 205B -5.97% 203B +6.19% 164B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HWAIL PHARMACEUTICAL CO.,LTD. 
